Therefore, these effects resulted in increased proliferation and invasion of OVCA 429 and OVCA 432 ovarian cancer cell lines in a process blocked by PAFR antagonist ginkgolide B and PAFR-specific antibody, as well as erlotinib; Src TKIs, PP2 and A25; and PI3K inhibitor, LY294002 [34]. Here, SRC is linked to ovarian carcinoma.